Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 5/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GPR6 | P46095 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29537104 | 1.00 | MET (0.35) | METTRPA1MAPK8PDE4BMAPK14 | |
| SCHEMBL29537702 | 0.91 | PTGS2 (0.33) | METPTGS2 | |
| SCHEMBL26075465 | 0.91 | PTGS2 (0.33) | METPTGS2 | |
| SCHEMBL29536806 | 0.85 | PDE4B (0.40) | METPDE4BBRD4 | |
| SCHEMBL25420084 | 0.85 | PDE4B (0.40) | METPDE4BBRD4 | |
| SCHEMBL26077874 | 0.84 | MAPK8 (0.33) | TRPA1MAPK8MAPK14PTGS2GPR6 | |
| SCHEMBL29536472 | 0.83 | BRD4 (0.46) | MAPK8MAPK14PTGS2BRD4 | |
| SCHEMBL25421846 | 0.83 | BRD4 (0.46) | MAPK8MAPK14PTGS2BRD4 | |
| SCHEMBL29537371 | 0.82 | MET (0.32) | METPDE4B | |
| SCHEMBL29536937 | 0.80 | L3MBTL1 (0.33) | TRPA1MAPK14PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| EP-4192582-A1 | KINASE INHIBITORS AND USES THEREOF | ABM Therapeutics Corporation (US) | 2023-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ERBB2, ERBB3, ERBB4 | MET 49/4885TRPA1 3692/4885MAPK8 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.